Oscar Health, Inc. (OSCR)
Locked

Oscar Health Earned Its Rerating on Expenses, Not on the $250 Million Everyone Is Arguing About

The expense transformation is real and is being given too little credit — though less of it is clean than the headline suggests; the underwriting result is partly borrowed from an estimate that will not settle until mid-2027.

On November 5 Oscar Health reported $5.14 billion of revenue, up 72% year over year, and $178.0 million of earnings from operations against a $129.3 million loss a year earlier, and raised its full-year outlook for the third time . The shares fell in both sessions that followed, closing November 6 down 7.6% at $30.65 — roughly a fifth below the $38.50 high the stock had touched within the same week, after the Democratic sweep of Congress sent exchange-exposed insurers sharply higher on November 4 . A beat that size being sold that hard is worth taking seriously as information.

Oscar is a monoline. Where Elevance and Centene spread their exchange exposure across commercial, Medicaid and Medicare books, Oscar sells individual and family plans on the ACA marketplaces, reports a single segment , and draws 91% of its direct policy premiums from subsidies paid by the Centers for Medicare & Medicaid Services . Alongside the insurance company sit three marketplace subsidiaries — Lucie, Trove Group and HealthInsurance.org — of which Lucie, a multi-carrier shopping and broker platform, is on track to sell roughly 800,000 policies in 2027 . That is strategically interesting and financially immaterial today; nothing in the valuation depends on it. What the valuation depends on is whether a monoline ACA underwriter that lost $396 million at the operating line in FY25 has genuinely changed, or has simply had a good year inside a cyclical risk pool.

My reading splits the difference in a way that matters. The expense transformation is real and is being given too little credit — though less of it is clean than the headline suggests. The underwriting result is partly borrowed from an estimate that will not settle until mid-2027. And the share price already reflects both, once you stop capitalizing a tax rate that cannot last.

The expense line is the part that isn't an actuarial judgment — but three-quarters of it, not all

Start with what is observable. Oscar's selling, general and administrative expense ratio fell 350...